Dermatology: Where are We Coming from and Where are We Going to?
作者信息
van de Kerkhof Peter C M
机构信息
Department of Dermatology, Radboud University Nijmegen Medical Centre , Nijmegen , Netherlands.
出版信息
Front Med (Lausanne). 2014 Oct 24;1:40. doi: 10.3389/fmed.2014.00040. eCollection 2014.
Abstract
摘要
相似文献
1
Dermatology: Where are We Coming from and Where are We Going to?
Front Med (Lausanne). 2014 Oct 24;1:40. doi: 10.3389/fmed.2014.00040. eCollection 2014.
2
The State of Ethnic Dermatology in Canada.
J Cutan Med Surg. 2017 Sep/Oct;21(5):464-466. doi: 10.1177/1203475417711110.
3
Dermatology practice in primary health care services: where do we stand in the Middle East?
Int J Dermatol. 2002 Jan;41(1):4-7. doi: 10.1046/j.1365-4362.2002.01294.x.
4
Pattern of paediatric dermatoses at dermatology clinics in Ile-Ife and Ilesha, Nigeria.
Paediatr Int Child Health. 2016 May;36(2):106-12. doi: 10.1179/2046905515Y.0000000012.
5
[A range of targeted treatments using monoclonal antibodies in dermatology. Current and future practice].
Rev Med Liege. 2009 May-Jun;64(5-6):334-8.
6
[Underestimation of dermatology based on ignorance and its impact on patient's health].
Rev Med Inst Mex Seguro Soc. 2015 Mar-Apr;53(2):250-3.
7
[Use of www.dermatoweb.net to support undergraduate teaching of dermatology].
Actas Dermosifiliogr. 2009 Dec;100(10):866-74.
8
The Tenth International Congress of Dermatology, in relation to occupational dermatoses.
Ind Med Surg. 1952 Oct;21(10):502-4.
9
Instruments to assess stigmatization in dermatology.
Postepy Hig Med Dosw (Online). 2017 Nov 3;71(0):901-905. doi: 10.5604/01.3001.0010.5607.
10
[Differential diagnosis of dermatoses in infants].
Med Klin. 1961 Sep 8;56:1533-6.
本文引用的文献
1
Monogenic human skin disorders.
Dermatology. 2014;229(2):55-64. doi: 10.1159/000362200. Epub 2014 Jul 8.
2
Secukinumab in plaque psoriasis--results of two phase 3 trials.
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
3
New and emerging therapies in psoriasis.
Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S37-41. doi: 10.12788/j.sder.0066.
4
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.
5
Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper.
J Dermatolog Treat. 2015 Apr;26(2):103-12. doi: 10.3109/09546634.2014.880396. Epub 2014 Feb 19.
6
Medical approaches to non-melanoma skin cancer.
Expert Rev Anticancer Ther. 2013 Dec;13(12):1409-21. doi: 10.1586/14737140.2013.856759.
7
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
8
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
Br J Dermatol. 2013 Nov;169(5):992-9. doi: 10.1111/bjd.12517.
9
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.
10
Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.
Br J Dermatol. 2013 Aug;169(2):306-13. doi: 10.1111/bjd.12341.
Zotero 插件